BVF INC/IL Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001056807

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 44 positions · Total reported value $3.91B · Top-10 concentration 65.6% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 34.8% · 5 new · 9 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +26.0% · vs SPY +11.2% · Prev Value $3.14B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, BVF INC/IL disclosed 44 equity positions with a combined reported value of $3.91B. The filing implies a focused portfolio: its ten largest positions account for 65.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were RVMD ($555.32M), KYMR ($444.01M), XOMA ($322.72M). By sector, the heaviest allocations are Health Care 91.6%, Financials 0.1%. Versus the prior quarter, allocation shifted toward Other (+5.7pp) and away from Health Care (-5.7pp).

Versus the prior quarter, BVF INC/IL opened 5 new positions, trimmed 9 and fully exited 2, a turnover rate of 34.8% of positions. The portfolio's overlap with the prior quarter was 85% of names.

The largest new positions opened in Q2 2026 were QTTB ($29.94M), ABSI ($27.37M), SGMT ($19.32M).

Of the 2 positions fully exited versus the prior quarter, the largest were CMPX ($41.08M), SEPN ($32.52M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • QTTB Q32 BIO INC · $29.94M
  • ABSI ABSCI CORP · $27.37M
  • SGMT SAGIMET BIOSCIENCES INC A · $19.32M
  • RACC RESEARCH ALLIANCE CORP III · $5.35M
  • ENTX ENTERA BIO LTD · $4.29M

Fully Exited (vs previous quarter)

  • CMPX COMPASS THERAPEUTICS INC · prev qtr: $41.08M
  • SEPN SEPTERNA INC · prev qtr: $32.52M

Insider Transactions (Form 4)

Latest BVF INC/IL buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-07-14 U XOMA Royalty Corp 772,000 — SEC filing
2026-07-14 U XOMA Royalty Corp 412,000 — SEC filing
2026-07-14 U XOMA Royalty Corp 2,773,545 — SEC filing
2026-07-14 U XOMA Royalty Corp 3,635,758 — SEC filing
2026-06-26 Sell Kymera Therapeutics, Inc. 51,858 $106.50 SEC filing
2026-06-26 Sell Kymera Therapeutics, Inc. 113,289 $106.50 SEC filing
2026-06-26 Sell Kymera Therapeutics, Inc. 627,597 $106.50 SEC filing
2026-06-26 Sell Kymera Therapeutics, Inc. 837,914 $106.50 SEC filing

All insider transactions →

Fund Profile

BVF INC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 44 positions worth $3.91B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 44 positions · $3.91B reported value (Q2 2026)
  • Top 10 holdings = 65.6% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 14.2%
  • Average position size: $88.89M

Sector Tilt

  • Health Care 91.6%
  • Financials 0.1%
  • Materials 0.0%
  • (classified holdings cover 92% of value)

Quarterly Activity

  • Q2 2026: 5 new, 6 added, 9 reduced, 2 exited
  • 24 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to be actively managing its portfolio with a focus on healthcare sector investments. The addition of new positions and significant increases in existing ones suggest a bullish outlook on the healthcare sector. 2. Key Moves: - Added: The fund added positions in Revolution Medicines Inc. (RVMD), Kymera Therapeutics Inc. (KYMR), Xoma Royalty Corporation (XOMA), and Alkermes PLC (ALKS). The most significant addition was to XOMA, with a 193.1% increase in shares. - Reduced: The fund reduced holdings in Kymera Therapeutics Inc. (KYMR) by 29.6%, Xencor Inc. (XNCR) by 2.7%, and Nektar Therapeutics (NKTR) by 6.6%. The largest reduction was in KYMR. - Hold: The fund maintained its positions in Moonlake Immunotherapeutics (MLTX), GH Research PLC (GHRS), and Xencor Inc. (XNCR). 3. Portfolio Structure: - Active/Passive: The fund is active, as evidenced by the significant changes in positions and the addition of new holdings. - Sector Bias: The portfolio is heavily biased towards the healthcare sector, with a significant portion of the total value allocated to healthcare stocks. - Risk Appetite: The fund shows a moderate risk appetite, with a mix of aggressive additions (XOMA) and more conservative holds (MLTX, GHRS). 4. Per-Holding One-Liner: - RVMD: Revolution Medicines Inc. focuses on developing novel therapies for cancer and autoimmune diseases. - KYMR: Kymera Therapeutics Inc. is engaged in the development of novel therapies for genetic diseases. - XOMA: Xoma Royalty Corporation is a biopharmaceutical company that licenses and acquires royalty interests in various biopharmaceutical products. - MLTX: Moonlake Immunotherapeutics is a biotechnology company focused on the development of novel immunotherapies. - GHRS: GH Research PLC is a biopharmaceutical company focused on the development of therapies for neurological and psychiatric disorders. - GPCR: Structure Therapeutics Inc. is a biotechnology company focused on the development of novel therapies for neurological and psychiatric disorders. - NKTR: Nektar Therapeutics is a biopharmaceutical company that develops novel therapeutics for cancer and chronic pain. - MIRM: Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of therapies for rare genetic disorders. - XNCR: Xencor Inc. is a biopharmaceutical company that develops engineered antibodies for the treatment of cancer, autoimmune, and inflammatory diseases. - ALKS: Alkermes PLC is a biopharmaceutical company focused on the development of novel therapies for central nervous system disorders. 5. One-Sentence Style Summary: The fund rebalanced this quarter with a bullish outlook on healthcare, emphasizing active management and sector-specific investments.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 91.6%
Financials 0.1%
Materials 0.0%
Other 8.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.97M $555.32M 14.20%
14.20%
Add
2 3.87M $444.01M 11.35%
11.35%
Reduce
3 7.59M $322.72M 8.25%
8.25%
Add
4 16.00M $311.54M 7.97%
7.97%
Hold
5 8.65M $232.52M 5.95%
5.95%
Hold
6 3.37M $180.70M 4.62%
4.62%
Reduce
7 2.39M $166.92M 4.27%
4.27%
Reduce
8 1.06M $123.63M 3.16%
3.16%
Reduce
9 7.13M $114.85M 2.94%
2.94%
Hold
10 2.15M $112.90M 2.89%
2.89%
Add
11 4.46M $107.95M 2.76%
2.76%
Hold
12 5.75M $104.72M 2.68%
2.68%
Hold
13 672.79K $102.82M 2.63%
2.63%
Reduce
14 3.65M $95.39M 2.44%
2.44%
Reduce
15 8.45M $92.65M 2.37%
2.37%
Hold
16 1.15M $84.38M 2.16%
2.16%
Reduce
17 2.55M $83.36M 2.13%
2.13%
Hold
18 5.30M $66.25M 1.69%
1.69%
Hold
19 8.70M $49.67M 1.27%
1.27%
Hold
20 2.75M $49.48M 1.26%
1.26%
Hold
21 19.82M $47.18M 1.21%
1.21%
Hold
22 1.48M $47.15M 1.21%
1.21%
Reduce
23 1.25M $41.56M 1.06%
1.06%
Hold
24 1.29M $41.10M 1.05%
1.05%
Hold
25 2.08M $38.36M 0.98%
0.98%
Add
26 2.88M $38.29M 0.98%
0.98%
Hold
27 2.35M $29.94M 0.77%
0.77%
New
28 3.00M $29.55M 0.76%
0.76%
Hold
29 5.84M $28.51M 0.73%
0.73%
Hold
30 2.36M $27.37M 0.70%
0.70%
New
31 6.29M $24.80M 0.63%
0.63%
Hold
32 28.16M $24.57M 0.63%
0.63%
Add
33 2.50M $19.32M 0.49%
0.49%
New
34 3.24M $14.76M 0.38%
0.38%
Add
35 765.29K $11.76M 0.30%
0.30%
Reduce
36 2.23M $10.43M 0.27%
0.27%
Hold
37 1.11M $6.55M 0.17%
0.17%
Hold
38 5.56M $5.45M 0.14%
0.14%
Hold
39 500.00K $5.35M 0.14%
0.14%
New
40 1.35M $5.15M 0.13%
0.13%
Hold
41 339.55K $4.94M 0.13%
0.13%
Hold
42 2.42M $4.29M 0.11%
0.11%
New
43 686.04K $2.59M 0.07%
0.07%
Hold
44 945.40K $274.07K 0.01%
0.01%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 80% R 80% F1 80% (modelled on 2026-Q1; 8/10 hit)

Low-confidence forecast This fund replaces about 22% of its Top-10 each quarter and backtests at F1 78% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 78% · recall 78% · F1 78% · avg rank error 2.2 · Top-10 turnover 22%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% MLTX · RVMD · AXSM · PTGX · KYMR · MIRM · OLMA · IONS · KURA · ACIU MLTX · KYMR · RVMD · FDMT · GHRS · JANX · MIRM · PTGX · IONS · OLMA
2024-Q2 80% 80% 80% MLTX · KYMR · RVMD · FDMT · GHRS · MIRM · PTGX · JANX · OLMA · IONS MLTX · RVMD · KYMR · IONS · MIRM · GHRS · PTGX · CGEM · OLMA · GPCR
2024-Q3 70% 70% 70% MLTX · RVMD · IONS · KYMR · MIRM · GHRS · PTGX · GPCR · CGEM · OLMA MLTX · KYMR · RVMD · MIRM · TYRA · OLMA · GPCR · CGEM · XOMA · AXSM
2024-Q4 70% 70% 70% MLTX · KYMR · RVMD · MIRM · GPCR · TYRA · OLMA · CGEM · XOMA · AXSM MLTX · KYMR · RVMD · AXSM · MIRM · XOMA · PTGX · GHRS · CGEM · ZYME
2025-Q1 90% 90% 90% MLTX · KYMR · RVMD · AXSM · MIRM · XOMA · GHRS · CGEM · PTGX · ZYME MLTX · AXSM · RVMD · KYMR · MIRM · PTGX · GHRS · XOMA · IONS · ZYME
2025-Q2 90% 90% 90% MLTX · AXSM · RVMD · KYMR · PTGX · MIRM · GHRS · XOMA · KURA · IONS MLTX · KYMR · RVMD · PTGX · AXSM · MIRM · GHRS · IONS · XOMA · ZYME
2025-Q3 70% 70% 70% MLTX · KYMR · PTGX · RVMD · AXSM · MIRM · GHRS · IONS · XOMA · ZYME KYMR · RVMD · PTGX · MLTX · CDTX · GHRS · MIRM · XOMA · GPCR · KURA
2025-Q4 70% 70% 70% KYMR · RVMD · PTGX · CDTX · MLTX · GHRS · MIRM · GPCR · XOMA · PVLA KYMR · RVMD · MLTX · GPCR · OLMA · MIRM · GHRS · XNCR · ZYME · PVLA
2026-Q1 90% 90% 90% KYMR · GPCR · RVMD · MLTX · OLMA · XNCR · GHRS · MIRM · ZYME · PVLA KYMR · MLTX · RVMD · NKTR · GPCR · MIRM · GHRS · PVLA · ZYME · XNCR
2026-Q2 ★ 80% 80% 80% KYMR · MLTX · RVMD · NKTR · GPCR · MIRM · GHRS · PVLA · XNCR · ZYME RVMD · KYMR · XOMA · MLTX · GHRS · GPCR · NKTR · MIRM · XNCR · ALKS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did BVF INC/IL buy in 2026-Q2?

In its 2026-Q2 13F filing, BVF INC/IL reported 44 equity positions worth $3.91B in aggregate; its largest disclosed positions were RVMD ($555.32M), KYMR ($444.01M), XOMA ($322.72M).

How large is BVF INC/IL's portfolio?

BVF INC/IL reported $3.91B of long equity holdings across 44 positions as of 2026-Q2. Top-10 holdings account for 65.6% of reported value.

What is BVF INC/IL's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bvf-inc-il/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →